Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746977 | 0.94 | LMNA (0.47) | ALDH1A1MAPTMAPK1HTTNPC1 | |
| SCHEMBL3094959 | 0.92 | ALDH1A1 (0.55) | ALDH1A1MAPTMAPK1HTTNPC1 | |
| SCHEMBL22587819 | 0.89 | ALDH1A1 (0.51) | ALDH1A1MAPTMAPK1HTTNPC1 | |
| SCHEMBL22716682 | 0.88 | ALDH1A1 (0.53) | ALDH1A1MAPTMAPK1HTTNPC1 | |
| SCHEMBL4635973 | 0.88 | ALDH1A1 (0.52) | ALDH1A1MAPTMAPK1HTTNPC1 | |
| SCHEMBL28696655 | 0.88 | ALDH1A1 (0.50) | ALDH1A1MAPTMAPK1HTTNPC1 | |
| SCHEMBL22605844 | 0.88 | ALDH1A1 (0.63) | ALDH1A1MAPTMAPK1HTTNPC1 | |
| SCHEMBL8246164 | 0.88 | ALDH1A1 (0.49) | ALDH1A1MAPTMAPK1HTTNPC1 | |
| SCHEMBL4637044 | 0.87 | MAPT (0.61) | ALDH1A1MAPTHTTNPC1RAB9A | |
| SCHEMBL24689326 | 0.87 | MAPT (0.64) | ALDH1A1MAPTMAPK1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004182-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-08 | — | — | EP | disclosed |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-13 | — | — | US | disclosed |
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| EP-2004182-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008119711-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119716-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119716-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119714-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119714-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119717-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119717-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119719-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119719-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119711-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | ALDH1A1 299/4885MAPT 584/4885MAPK1 1643/4885 |
| US-20100280071-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | ALDH1A1 299/4885MAPT 584/4885MAPK1 1643/4885 |
| US-20120316202-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | ALDH1A1 1046/4885MAPT 502/4885MAPK1 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.